The retinal pigment epithelium (RPE) interacts closely with photoreceptors to maintain visual function. In degenerative diseases such as Stargardt disease and age-related macular degeneration, the leading cause of blindness in the developed world, RPE cell loss is followed by photoreceptor cell death. RPE cells can proliferate under certain conditions, suggesting an intrinsic regenerative potential, but so far this has not been utilised therapeutically. Here, we used E2F2 to induce RPE cell replication and thereby regeneration. In both young and old (2 and 18 month) wildtype mice, subretinal injection of non-integrating lentiviral vector expressing E2F2 resulted in 47% of examined RPE cells becoming BrdU positive. E2F2 induced an increase in RPE cell density of 17% compared with control vector-treated and 14% compared with untreated eyes. We also tested this approach in an inducible transgenic mouse model of RPE loss, generated through activation of diphtheria toxin-A gene. E2F2 expression resulted in a 10-fold increase in BrdU uptake and a 34% increase in central RPE cell density. Although in mice this localised rescue is insufficiently large to be demonstrable by electroretinography, a measure of massed retinal function, these results provide proof-of-concept for a strategy to induce in situ regeneration of RPE for the treatment of RPE degeneration.
INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly worldwide, affecting 30-50 million individuals, 14 million of which are blind or severely visually impaired. [1] [2] [3] Due to the rapidly aging population, the number of persons suffering from advanced forms of AMD will increase by 50% in 2020. 4 Currently, there is neither a preventive or curative treatment for AMD. For non-neovascular AMD affecting the majority of patients (492%), no established treatment options exist. For neovascular AMD, the most widely used treatment involves administration of antibodies against vascular endothelial growth factor (VEGF) to prevent the formation of new blood vessels. Underlying all forms of AMD is a dysfunctional retinal pigment epithelium (RPE). RPE function is essential for maintaining photoreceptor health by providing growth factors and cytokines, 5 forming the outer blood retina barrier, phagocytosis of photoreceptor outer segments and processing retinoids for phototransduction. The continual phagocytosis of shed photoreceptor discs is associated with a high level of oxidative stress that may lead to loss of RPE. 6 The highest turnover rate of shed photoreceptor discs is in the macula where photoreceptor density is highest. 7 In the adult human eye, the RPE is a non-dividing cell system, 8, 9 and death of RPE cells is not compensated by cellular regeneration. 7, 10 In retinal degenerations, when RPE is lost, surrounding RPE cells enlarge to fill the space. 11 This increases metabolic load on individual RPE cells resulting in further damage and loss. Replacing RPE cells by transplantation or inducing controlled proliferation of RPE cells may prevent disease progression.
Various attempts have been made to replace diseased RPE in the central retina, but none so far has proved efficient and safe enough for standard treatment. Macular translocation surgery aims to relocate the central retina to an area of healthy RPE. 12 Despite a high complication rate, 13 gain of visual function in some patients provides a proof-of-concept that RPE re-population under the macula restores vision.
14-17 RPE transplantation, using autologous RPE sources such as iris pigment epithelium 18 or RPE from the periphery, [19] [20] [21] has been investigated for over three decades. 22 Recently there have been several clinical trials involving RPE derived from human embryonic stem cells 23 or human induced pluripotent stem cells. 24, 25 Despite promising results, to date there is no consensus over the best method to treat RPE defects and it remains uncertain how effective this approach might be.
Here we propose a new strategy to regenerate RPE in situ by making use of its natural proliferative potential. We sought to overcome the intrinsic barriers to RPE proliferation and induce regeneration by mitosis in vivo using lentiviral vector-mediated transfer of the gene encoding the transcription factor E2F2, which can induce cells to bypass G1 arrest. [25] [26] [27] The E2F transcription factor family and the product of the retinoblastoma tumour suppressor gene (Rb) can be described as opposing molecules that control the G1 to S phase transition, 26 whereby Rb is recognized as a tumour suppressor and key inhibitor of E2F, a central transcriptional activator. 27 The E2F transcription factor family control a variety of genes involved in DNA replication such as thymidine kinase, thymidylate synthase, dihydrofolate reductase -virtually the entire apparatus of initiation factors that assemble a pre-replication (b, c) Increase in protein levels of E2F2 compared with control, assessed by Western blot (9-fold increase after 2 days, threefold increase after 7 days; two-tailed t-test; densidometric quantification, 5 min and 30 min indicate different exposure times, mean+s.d.). (b, d) Levels of proliferation marker Cyclin D1 increased following E2F2 overexpression (2-and 3-fold, on day 2 and 7, respectively). (e) E2F2 overexpression induces Ki67 expression. On day 7 and 14 post transfection, E2F2 caused a 2.3-fold and 1.7-fold increase in Ki67 positive nuclei compared with controls (40 vs 18 and 7% vs 4% of total cells; two-tailed t-test). (f) E2F2 overexpression induces BrdU uptake. BrdU-positive nuclei were increased by 3.5-and 5.4-fold at 1 and 2 weeks post transfection, respectively (two-tailed t-test).
In situ RPE regeneration by E2F2 D Kampik et al complex at the transition from G1 to S phase. 28 While E2F-1 to -4 all induce S phase progression with decreasing efficacy, E2F1 uniquely also induces apoptosis. 29 In this study, we therefore selected E2F2 for overexpression to overcome cell cycle arrest in RPE cells. We test this concept in vitro, in wildtype mice and in an inducible RPEdeficient mouse model (RPE CreER /DTA) 11 and provide evidence for in situ RPE cell proliferation.
RESULTS AND DISCUSSION
The effect of E2F2 overexpression was assessed in vitro on ARPE19 cells. Growth arrested ARPE19 cells, as shown by an absence of nuclear Ki67 (Supplementary Figure S1 ), were transfected with pCMV-E2F2. E2F2 mRNA persisted at a 41000-fold increase 21 days post transfection (Figure 1a) , inducing E2F2 protein overproduction by 9-fold after 2 days, and threefold after 7 days compared with control plasmid (Figures 1b and c) . E2F2 overexpression coincided with increased protein levels of proliferation marker Cyclin D1 (Figures 1b and d) . Two days after transfection of growth-arrested monolayers with pCMV-E2F2, or control plasmid pcDNA3-EGFP, over 86% of cells were Ki67-positive in both groups. However, on day 7 and 14 post transfection, E2F2 overexpression resulted in a 2.3-fold and 1.7-fold increase respectively in Ki67-positive nuclei compared with pCDNA3-EGFP controls (P o 0.05, t-test; Figure 1e ) suggesting that E2F2 stimulates an increase in proliferation in vitro. Similarly, after an initial increase in uptake of bromodeoxyuridine (BrdU), a synthetic thymidine analogue incorporated into newly synthesized DNA, in both control and E2F2-transfected cells, BrdU uptake in E2F2-treated cells increased by 3.5-and 5.4-fold, at 1 and 2 weeks respectively, (Figure 1f ). Together, these results suggest that E2F2 overexpression can lead to specific induction of cell proliferation in contact-inhibited ARPE19 cells.
To test whether the same approach might be effective in vivo, the E2F2 construct was packaged into a non-integrating lentiviral vector, LNT-E2F2, and administered subretinally, causing E2F2 overproduction and nuclear localization in the RPE (Figure 2a Figure S2b) . In 18-month-old mice (n = 3 mice for pairwise left-right comparison against LNT-hrGFP), we tested whether age of the animal may affect the proliferative effect of E2F2 overexpression in vivo. The similar increase in BrdU uptake upon E2F2 overexpression in young and 18-month-old mice suggests this approach was not restricted by the age of the recipient (Figure 2f ).
To assess whether the increase in cell proliferation markers resulted in increased RPE cell density, 8-week-old adult mice received subretinal injections of LNT-E2F2, LNT-GFP or medium. Fifty-three phalloidin-stained RPE flatmounts of 30 mice were imaged 10 days after treatment (Figure 3a ). Only transduced areas around the injection site were evaluated; areas directly adjacent to the injection site that were severely dysmorphic were excluded. Compared with controls, LNT-E2F2 treated eyes presented with variable cell size and morphology as would be expected when existing cells divide in situ and two new cells take up the available space. It should be noted that the presence of two nuclei constitutes normal morphology for a mouse RPE cell. Cell outlines were partially disrupted and smaller cells gathered in clusters without gaps between cells. No overt pathology of the neuroretina was observed in these eyes. RPE cell density was quantified on masked samples by counting cells outlined by phalloidin staining. Untreated age-matched eyes served as an additional control. One-way analysis of variance revealed highly significant differences among groups (P = 0.0002, Figure 3b ). LNT-E2F2-injected eyes presented an RPE cell density significantly higher that all three control groups (P = 0.0011-0.0071, Tukey's multiple comparisons test). No significant difference was observed between the control groups (P40.6). These data reveal that lentiviral-mediated E2F2 overexpression in the RPE can induce an increase in RPE cell density by about 20% in wildtype RPE.
We next investigated possible effects of LNT-E2F2 injection and the resulting increase in RPE density upon the function of the overlying photoreceptors and gross structure of the neuroretina. As before 8-week-old adult mice received subretinal injections of LNT-E2F2, LNT-GFP or were left uninjected. Retinal function was then assessed by electroretinography (ERG) at 10 and 30 days post injection (DPI) and tissue collected for histological analysis at both timepoints. Analysis of the ERG data revealed no significant differences between the LNT-E2F2 and LNT-eGFP treated groups at either timepoint under both photopic (Supplementary Figure S3a) and scotopic (Supplementary Figure S3b) conditions. Additionally, histological assessment of neuroretina revealed no apparent differences in retinal morphology between the injected groups at either timepoint (Supplementary Figure S3c) . In all examined eyes, retinal morphology appeared normal.
To test whether E2F2 overexpression can also increase cell density in diseased RPE, we assessed LNT-E2F2 administration in double-transgenic RPE CreER /DTA mice. These carry a tamoxifeninducible Cre recombinase driven by the RPE-specific monocarboxylate transporter 3 (SLC16A8) promoter, and a diphtheria toxin A chain (DTA) gene rendered transcriptionally silent by a floxed stop sequence. Activation of Cre by tamoxifen injection induces DTA expression, causing partial RPE cell loss. Four double transgenic RPE CreER +/ − /DTA +/ − and four wildtype mice received intraperitoneal tamoxifen injections (postnatal days 12-24) to induce RPE ablation in the transgenic mice only. At four months of age, RPE showed polymorphous cells with increased cell size compared to wildtype RPE, but the monolayer remained intact without holes (Figure 4a ). Mean cell density was reduced by 15 ± 5% (P = 0.0082, Figure 4b ). Regional analysis revealed that the reduction in cell density in transgenic compared to wildtype mice In the LNT-E2F2 group, a high linear correlation was observed (Pearson correlation coefficient 0.9170, r 2 = 0.841, P o0.0001), while no correlation was observed for the medium injected control group. (e) The LNT-E2F2 injected group showed a significant increase in E2F2 and BrdU staining compared with both control groups (mice aged 9 weeks, n = 4 eyes per group from different animals, Po0.0001, oneway analysis of variance; ***P o0.0001 in Tukey's multiple comparisons test, no significant difference between both control groups; bars represent mean ± s.d.). E2F2 and BrdU positive nuclei were counted in 5 HPF per eye and averaged. (f) 18 months old mice (n = 3 mice for pairwise left-right comparison) demonstrate a similar increase in BrdU uptake upon E2F2 overexpression (*P = 0.0463, two-tailed paired t-test; bars represent mean ± s.d.).
In situ RPE regeneration by E2F2 D Kampik et al was most pronounced in the central RPE, where there was a 24 ± 10% decrease (P = 0.0231, Figure 4c ), in line with our previous findings.
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RPE damage was induced in 4 transgenic mice as described above. At 4 months, treatment vector LNT-E2F2 and control vector LNT-GFP were injected subretinally into right and left eyes, respectively. Animals received intraperitoneal BrdU injections daily from day 4 to day 10 afterwards. On day 10, RPE-choroid-sclera complexes were immunostained for BrdU and ZO-1 and flatmounted. We analyzed both treated and untreated areas, that is, areas outside the injection bleb, of the flatmounts throughout all eyes of both groups, as shown schematically in Figure 5a (injection sites were excluded). In RPE CreER /DTA transgenic LNT-E2F2-treated eyes, we observed BrdU uptake comparable with wildtype C57BL6/J mice after LNT-E2F2 treatment, while LNT-GFP injected control eyes showed almost no BrdU uptake (Figures 5b,  c) . LNT-E2F2 treatment of RPE CreER /DTA mice increased BrdU uptake by 9-fold ± 3.4 (mean ± s.d., P = 0.0173, paired t-test, n = 4 eyes). Following LNT-E2F2 treatment, overall cell density was increased 20 ± 11% (mean ± s.e.m.) compared with control vector. However, this did not reach statistical significance (P = 0.2043, unpaired t-test). Regional analysis revealed that the largest increase in cell density was in the centre in RPE ablated mice (Figure 5d ). In the central retina where Cre-induced degeneration . Quantification of RPE cell density was done on masked samples by counting cells. Six micrographs per eye were counted and averaged, for each condition n = 15 eyes from different animals, for medium controls n = 8. Numbers in graph represent mean cell density; error bars represent SD. One-way analysis of variance revealed highly significant differences among groups (P = 0.0002). LNT-E2F2 treatment increased cell density by 17 ± 13% compared to LNT-GFP, by 21 ± 14% compared to medium injection, and by 14 ± 7% compared to untreated eyes (Tukey's multiple comparisons test).
In situ RPE regeneration by E2F2 D Kampik et al was most prominent, we saw a significant increase in cell density of 34 ± 10% after E2F2 overexpression (P = 0.0458). In the midperiphery and periphery, smaller non-significant increases in cell density were observed. RPE cells have an inherent capacity to proliferate. In vitro, mammalian RPE cells can be cultured for up to 6 months, undergoing several population doublings. 30 In vivo, RPE cells can proliferate as a natural reaction to disruption of the subretinal space during retinal detachment. [31] [32] [33] A necessary precondition for this kind of proliferation is disruption of cell-cell junctions to overcome contact inhibition. By E2F2 gene transfer, we were able to induce proliferation in situ, without disruption of the RPE monolayer, and we showed that the biggest effect was achieved in the RPE area with the lowest cell density.
Subretinal injection itself is not free of trauma and might have induced some proliferation. However, injection of LNT-E2F2 vector caused limited BrdU uptake in cells evenly distributed throughout the injection area. Cells in the E2F2 treatment group showed variable cell size and smaller cells gathered in clusters, potential signs of toxicity or the results of replication. If toxicity were the prevailing factor for altered morphology, we would expect dying cells to leave the monolayer and leaving gaps between cells. Since the RPE monolayer remained intact, we are confident that the cell morphology in the E2F2-treated RPE reflects the effects of cell division. BrdU uptake is a sign of DNA synthesis and therefore cell cycle progression from G1 to S phase, but this does not always signify completion of mitosis. We therefore focused on cell density as the main endpoint. To compensate for any effect of the injection trauma, we added untreated eyes that never received any subretinal injection as controls. Untreated eyes showed a slightly higher cell density compared with the controls injected with LNT-GFP or medium, possibly indicative of minor, injectionrelated cell loss, but this was not significant. The highest cell density was seen in the LNT-E2F2 treatment group, showing a significant increase of 14% compared with untreated RPE and 21% compared with control transduced RPE.
As for 9-week-old adult mice, we observed similar cell cycle progression in mice older than 18 months, which corresponds to a human age of 450 years, when age-related changes of the macula become apparent. However, mouse RPE does not show age-related changes comparable to human, and any extrapolation of our findings to patients with AMD calls for caution. Older human RPE cells in the central macula exposed to life-long oxidative stress may not be capable of undergoing a full cell division. Del Priore et al. 10 found that the proportion of apoptotic cells in human RPE increased significantly with age, possibly amounting to a loss of 20% of the macular RPE per decade in older human eyes. Interestingly, apoptosis was confined to the central region. In apparent contrast to Del Priore, Ach et al. 34 showed that in the centre, human RPE cell density remains stable over lifetime. This discrepancy may be explained by RPE undergoing a life-long rearrangement, for example by migration from the periphery, possibly in combination with mitosis. In human adult RPE mitosis is detected at a very low rate, but only in the periphery. 10, 35 By E2F2 transfer, we may be harnessing a natural process of mitotic regeneration that is latent in the adult mammalian retina. In the transgenic mouse model, which we utilize as a model for RPE cell disease, no spontaneous mitotic regeneration was detected, instead cells expanded to up to 20 times their normal size, similar to what is observed in AMD patients. 32 Furthermore, we observe the presence of BrdU positive cells throughout the treatment area and the greatest proliferative effect of E2F2 transfer in the centre where cell density was lowest. This indicates that the E2F2 triggers mitosis of cells in situ rather than recruiting cells from the periphery.
We and others have previously established that alterations made to the state of the cell cycle or cell-cell adhesion signalling pathways can result in de-differentiation of the RPE and the cells may undergo epithelial mesenchymal transition. This results in a marked loss of RPE cell identity both in terms of cell morphology and gene expression profile. 36, 37 Whilst transduced RPE (either by LNT-E2F2 or LNT-GFP) do display some morphological differences from untreated cells, the changes observed are much less severe than those seen in EMT in which cuboidal cell shape is lost. However, to examine whether any de-differentiation was occurring at the level of gene expression, we performed immunohistochemical staining for RPE65, a retinoid isomerohydrolase vital for RPE function. Transduction of the RPE with lentiviral vectors results in very sharp delineation of the transduced area. At 10 days post-injection the RPE65 signal was relatively homogenous across the boundary between the transduced and untransduced area in both LNT-E2F2 and LNT-GFP-injected eyes, indicating little loss of RPE cell identity in transduced cells ( Figure 6 ).
While this study primarily focused upon the direct effect of E2F2 overexpression within the RPE, we also found no indication of an indirect effect upon the overlying photoreceptors, in terms of either structure or function within wildtype mice. It should be noted, however, that loss of vision in conditions such as AMD is thought to be a result of photoreceptor cell death as a consequence of RPE pathology. Any therapeutic strategy aiming to preserve or restore RPE integrity must therefore be applied prophylactically and the degree of photoreceptor degeneration will be critical in defining the treatment window.
Although no sign of neoplastic growth was seen over the timeframes used in these experiments, continuous E2F2 overexpression may lead to a tumorigenic event, as the protein in implicated in retinoblastoma and glioblastoma. 38 In these proofof-concept experiments, we used non-integrating vectors resulting in episomal transgene copies, which will be diluted from the nucleus with every cell division. It is, however, possible that a temporary over-expression of E2F2, as we attempted here, could result in the establishment of a positive feedback loop that maintains the transduced cells within the cell cycle. 39 It may therefore be necessary to characterise more fully the effect of transient E2F2 overexpression upon the RPE cell cycle in vivo and implement additional safety measures. For example, an inducible promoter could be used to further control duration of expression, or a reverse transcriptase-defective lentiviral vector could be used, where reverse transcription of the transgene into DNA is prevented and the protein translated transiently from RNA templates. 40 In summary, our work shows that viral vector mediated gene delivery of E2F2 can induce proliferation in healthy and diseased RPE cells in vivo and that this approach can increase cell density of RPE cells preferentially in areas of low density, where contact inhibition may be lowest. In mice, where assessments of vision are generally massed retinal responses, this localised rescue would not be sufficiently large to be able to detect improved vision. However, in the human eye, this approach may provide an alternative to RPE cell transplantation by paving the way for an in situ regenerative approach to treat RPE cell pathology in Stargardt disease and AMD.
MATERIALS AND METHODS
Recombinant non-integrating lentiviral vectors Self-inactivating VSV-G pseudotyped lentiviral vectors were produced using the packaging plasmid pCMVΔR8.74D64V as described previously. 41, 42 After transfection of HEK293T cells, vector particles were harvested from culture supernatant at 48 and 72 h post transfection and purified/concentrated by filtration (0.45 μm) and ultracentrifugation and suspended in serum-free OptiMEM at 10 7 to 10 8 transducing U ml − 1 . See Supplementary Methods for details.
In vivo experiments All animals were cared for in accordance with the UK Animal Scientific Procedures Act 1986 and procedures were in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Female wild-type C57BL6/J mice (Harlan Laboratories, Bicester, UK) were used aged 6-8 weeks or up to 18 months. In transgenic male and female RPE CreER /DTA mice 11 RPE degeneration was induced by three intraperitoneal injections of 50 μg tamoxifen during postnatal days 12-24. Transscleral subretinal injections were performed as previously described, 43, 44 see Supplementary Methods. Per eye, two injections of 2 μl of viral suspension (5 × 10 7 vector particles per ml) were injected into the subretinal space. Group sizes were based on estimated variation and effect size. Animals and treatment eyes were not randomized.
Cell counts Quantification of RPE cell density was done on confocal micrographs of masked samples by manually counting cells outlined with phalloidin or ZO-1 (using NIH ImageJ software, http://rsbweb.nih.gov/ij/, Version 1.46a). Masking was done on two levels: the flatmount slides were masked before imaging by an independent observer. Image acquisition and image analysis was done by different researchers, and the image labels were again masked. Six micrographs per eye acquired in a standard pattern were counted and averaged.
Statistical analysis Student's t-test or analysis of variance tests were used as indicated for each experiment in the figure legends. Variance within groups was estimated to determine similarity between groups being compared. P o0.05 was deemed significant. Figure 6 . Lentivirus-mediated overexpression of E2F2 does not lead to dedifferentiation of RPE cells, as evidenced by the presence of RPE65. Staining for RPE-specific protein RPE65 in RPE flatmounts 10 days after subretinal administration of LNT-E2F2 showed no consistent decrease in cells positive for E2F2 protein in the nucleus, compared with E2F2 negative cells. RPE transduced with LNT-GFP control virus and no-primary control samples are provided as controls. Scale bar = 50 μm.
